Prostate Specific Antigen as a risk factor for skeletal metastasis in Black African men with Prostate Cancer: a Case Control study
|
|
- Emerald Melton
- 5 years ago
- Views:
Transcription
1 Prostate Specific Antigen as a risk factor for skeletal metastasis in Black African men with Prostate Cancer: a Case Control study ABSTRACT Prostate cancer is the commonest non cutaneous cancer in males. Men of African origin are at significantly higher risk as reflected in higher incidence and mortality rates in this racial group. Metastases incidence increases in parallel with serum levels of Prostate Specific Antigen (PSA), contributing significantly to morbidity and mortality. Staging of disease involves bone scans, which are sensitive in detecting skeletal metastases. Suggestions they may be omitted in some situations in patients with low prostate specific antigen levels, have drawn attention to the matter. In this case control study, using Radiology and Pathology records, a registry of prostate cancer patients recorded as being of Black African ethnicity was assembled. Images were presented to image reviewers blinded to the prostate specific antigen level, to determine presence of skeletal metastases. The risk factor for the outcome of interest (skeletal metastases) was prostate specific antigen level above 20ng/ml. Reliability of image reporting was also assessed. Of 122 patients, 50 (41%) had skeletal metastases, while these were absent in 72 (59%). The prevalence of metastases among the high prostate specific antigen group was 55.9% (95% CI 44.1% to 67.7%) and 22.2% (95% CI 11.1% to 33.3%) among the normal/low prostate specific antigen group. The Odds Ratio (OR) for skeletal metastases in the exposed (high prostate specific antigen) group was 4.4 (95% CI, 2.01 to 9.78.) Intra-observer agreement on image interpretation was 88.5% with a Kappa statistic of Relatively higher prevalence of skeletal metastasis is seen in regional Black African males with prostate cancer, at both low and high prostate specific antigen levels. Bone scanning in this population should therefore be considered even at prostate specific antigen levels below 20ng/ml. 1
2 Keywords: Prostate Cancer, Prostate Specific Antigen, Skeletal Metastases, Bone Scan, Black African INTRODUCTION Carcinoma of the prostate is the commonest non-cutaneous cancer in males, and the second most common cause of cancer deaths in males. 1 Its incidence rises significantly after the age of 50, and this cancer is diagnosed in one in six men during their lifetime. Multiple aetiological factors are implicated in the development of prostate cancer. Increasing age, a family history of disease, diet and genetic factors have all been linked. Amongst the most striking factors related to development of prostate cancer is race. Significantly higher rates of prostate cancer are seen in Blacks compared to Caucasian, Hispanic and Asian males. Age adjusted incidence rates (between ) were per 100,000 (African Americans) versus per 100,000 (Caucasians) respectively. 1 This placed incidence among the American Black men 1.6 times higher than white men. In addition, the death rate amongst African Americans was 2.4 times higher than Caucasians in the same time period (53.6 versus 26.3 per 100,000.) The differences in incidence and mortality are greater still, when comparing rates in African Americans to those among Hispanics, American Indians and Asians suggesting African Americans are not just at higher risk of development of prostate cancer, but also appear to develop more aggressive disease. Prostate cancer is the commonest cancer in Africa and Sub-Saharan Africa. In Eastern Africa, age adjusted incidence rates for prostate cancer are the second highest in this region after Kaposi sarcoma and oesophageal carcinoma. The disease burden in Africa appears to be significant. 2 2
3 Prostate Specific Antigen is produced in the prostatic epithelium but also by tumour cells. A combination of increased cell burden and distorted glandular architecture allowing escape of prostate specific antigen into systemic circulation is responsible for the increased levels of prostate specific antigen in prostate cancer. The skeletal system is one of the commonest sites of metastasis, found in approximately 85% of patients dying from prostate cancer. These metastases are predominantly osteoblastic. The bone scan (bone scintigraphy) is the most commonly performed procedure for whole body screening and assessment of skeletal metastasis (Figure 1). As a baseline investigation, it stages disease, demonstrates disease extent where metastases exist, and provides a benchmark for follow up scans when assessing response to treatment. The technique provides complementary information to the anatomical information provided by radiography, by demonstrating the metabolic changes induced by bone pathology. Due to the osteoblastic nature of prostatic cancer metastases, metastatic deposits manifest as areas of increased tracer uptake. In extensive metastatic disease burden, diffuse uptake is seen in throughout the axial skeleton giving a superscan appearance. Although the technique is relatively less specific, it has substantially higher sensitivity compared to radiography. Accurate disease staging can lead to more appropriate decision making and advice to patients. Management differs significantly in patients with metastatic disease, where the goal of therapy is palliative, symptom control and disease suppression, versus eradication of disease. Performing bone scans in patients with prostate specific antigen levels below 20ng/mL remains a grey area in clinical practice. The American Urology Association guidelines in their best practice statement of 2009 state that bone scans should be considered at prostate specific antigen levels below 20ng/ml if the tumour s Gleason score is eight or more or there is locally advanced 3
4 disease ( T3). 3 By contrast guidelines by the European Association of Urology state that in locally advanced disease or poorly differentiated tumours, bone scans should be performed regardless of the prostate specific antigen value. 4 The Japanese Urological Association suggests bone scans may be eliminated when prostate specific antigen levels are less than 10ng/mL in patients with well moderately differentiated cancers. 5 A systematic review examined the findings from 48 research reports, 23 of which correlated baseline bone scan findings as well as prostate specific antigen levels. Of 8644 patients, 16.8% had metastases. Detection rates were 2.3%, 5.3% and 16.2% in patients with prostate specific antigen levels less than 10, 10.1 to 19.9 and 20 to 49.9 ng/ml, respectively. 6 This meta-analysis may be taken as a global overview. However, men in the East African region may be considered at higher risk of developing skeletal metastases on a basis of ethnicity or other factors, based on the observation of higher incidence of and more aggressive prostate cancer in other Black populations worldwide. The present study was undertaken so as to generate data on prostate cancer metastasis to inform local and regional clinical practice. MATERIALS & METHODS Based on a hypothesis that metastasis is more common than the global estimate in our population, a sample size calculation determined that a sample size of 120 (40 cases and 80 controls) were required to detect an Odds Ratio (OR) difference of 4 between patients with mildly elevated prostate specific antigen (<20 ng/ml) and high prostate specific antigen ( 20 ng/ml), at 91% power. This was derived from pilot study data entered into a power and sample size calculator ( where it was shown that to detect a low Odds Ratio at a high power, a moderate number of cases were required (see 4
5 Appendix 1.) Patients with histologically confirmed prostate cancer who had a bone scan between the months of August 2011 to January 2013 at the Aga Khan University Hospital, Nairobi, were consecutively collected for this retrospective case control study, which was approved by the Research Ethics Committee (Ref No: 2012/REC-08(V2). Cases were defined as patients with histologically proven prostate cancer with skeletal metastases. Controls were defined as patients with histologically proven prostate cancer without skeletal metastases. The risk factor for outcome of interest (skeletal metastases determined by bone scan) was a prostate specific antigen level greater than or equal to 20ng/ml. Inclusion criteria included Black African patients with histologically confirmed prostate cancer and a serum prostate specific antigen test within 3 months of the bone scan who underwent bone scan for disease staging. Cases with bone metastases due to malignancy other than prostatic cancer, post-therapy follow up bone scans, equivocal cases without complementary images and bone scans reported by a radiologist other than the Nuclear Physician were excluded from the study. An initial listing of potentially eligible cases was acquired from the departmental patient register. The indication for the scan was confirmed from the radiology request form. In the few circumstances where this information was not provided, confirmation of the scan indication was made from the patient s file. Following collection of these data, the listing of cases was crossreferenced with Pathology department records to obtain details of histopathology where this had been carried out at the hospital. Pathology reports from other hospitals were included where available. Data collection began with the most recently performed bone scans to assess for prostate cancer skeletal metastases, and proceeded retrospectively. Sampling of patients was stratified into two groups: mildly elevated or normal prostate specific antigen (less than 20ng/mL,) and those with highly elevated prostate specific antigen (greater than 20 ng/ml.) The 5
6 total number of patients acquired was only slightly greater than the desired sample size therefore sampling was non random, and all eligible cases were included in the analysis. Prostate specific antigen levels are routinely collected from patients prior to the bone scan. Patient ethnicity was confirmed from the patient registration section of respective patient files, where this information is routinely recorded according to hospital administrative procedures. Data including patient identifiers were collected by one investigator. Details including patient name, hospital number and prostate specific antigen level were entered into a primary data collection table and each record was coded providing anonymity of the patient dataset and achieving blinding of subjects to the image reviewers. Coded images were presented to the image reviewers who entered data into a separate data collection table. Technetium-99 metastable Methylene Diphosphonate (99mTc-MDP) whole body bone scans were carried out on a dual head gamma camera (Millennium MG, GE Medical Systems) 3-4 hours following IV injection of Technetium-99 metastable Methylene Diphosphonate. Image acquisition times for a whole body scan were typically 20 minutes (camera speed of 11cm/sec) however these varied depending on the amount of activity injected. Lower injected activities require longer scan times. A matrix of 1024 x 256 was used with a Low Energy High Resolution collimator. If necessary, spot views of an area of interest were acquired. Five hundred thousand counts were obtained of this site. Images were analysed by a Nuclear Physician (expert reviewer) with over 15 years of experience in nuclear medicine, and a registrar with cumulative total of 5 months training in nuclear medicine. Coded images were uploaded onto the hospital picture archiving and communication system (PACS) to a folder specific for the purposes of the study. Through this system, images 6
7 were presented to the image reviewers using Agfa picture archiving and communication system and image viewing software, on a high resolution viewing monitor. The image reviewers were blinded to the results of the prostate specific antigen. In cases with metastatic disease sites of skeletal metastases were listed by the nuclear physician. Results of the Nuclear Physicians repeat report were compared with the original so as to determine intra-observer variability, and comparison between the registrar s report with the Nuclear Physicians repeat report to test interobserver variability. For comparison with prostate specific antigen levels the analysis was based on the expert reviewer s repeat report. In equivocal cases, the image reviewers were provided with complementary images, in the same coded manner. Prostate specific antigen levels in patients with and without skeletal metastases and summary statistics for the distribution of prostate specific antigen levels were calculated. Potential statistical associations between prostate specific antigen and skeletal metastases were estimated using Chi square statistics. Odds ratio of skeletal metastases between low and high prostate specific antigen groups were calculated. To determine the prevalence of skeletal metastases in patients with prostate specific antigen below 20ng/ml a two-sample test for proportions was applied using the Global estimate of 3.5% for comparison. 6 Assessment of intra-observer and inter-observer agreement for bone scans was quantified using Cohen s Kappa and percentage of agreement. RESULTS Within the 122 patient data sets included, 50 (41%) were found to have skeletal metastases, while 72 (59%) had no skeletal metastases detectable on bone scan. Sixty-eight of the 122 prostate specific antigen values (55.7%) were greater than or equal to 20 ng/ml, whilst 54 7
8 patients (44.3%) were considered unexposed on the basis of a prostate specific antigen level of below 20 ng/ml. Amongst patients with and without skeletal metastases, prostate specific antigen levels are summarised in Table 1 and Figure 2.To illustrate the actual range of prostate specific antigen values in the sample population, the mean prostate specific antigen in the unexposed group (prostate specific antigen less than 20ng/ml) was 10.2 ± 5.0 ng/ml ( ng/ml) and median prostate specific antigen was 10ng/ml. Within the exposed group (prostate specific antigen greater than 20ng/ml), the mean prostate specific antigen was ± 86.0ng/ml ( ng/ml.)the median prostate specific antigen value was 86ng/ml. In the present study, the Odds Ratio for skeletal metastasis was 4.4 (95% CI, ) in the exposed (high prostate specific antigen) group. The prevalence of metastases among this high prostate specific antigen group was 55.9% (44.1% to 67.7%) and 22.2% (11.1% to 33.3%) among the normal or low prostate specific antigen group. A two-sample test of proportions was used to compare these proportions with global estimates of 42.6% and 3.5% respectively. The prevalence of metastases among high prostate specific antigen group differed by 13.3% (95% CI, 1.2% %; P=0.031) compared to the global estimate. Among the low prostate specific antigen group the prevalence differed by 18.7% (95% CI, 7.6% %; P=0.001) from the estimated global average. Sites of skeletal metastases varied, with the spine, pelvis and rib cage representing the commonest sites. These data are summarised in a bar graph format (Figure 3.) Intra and inter-observer agreement of reporting was performed using kappa statistics. There was an 88.5% agreement between the expert reviewer s original and repeat reports, giving a kappa 8
9 value of 0.76, indicating substantial agreement. Agreement between the registrar and expert reviewer reports was 85.3%, with a kappa value of 0.70, also indicating substantial agreement. DISCUSSION The increasing role of prostate specific antigen as a screening tool for prostatic disease has led to an increase in diagnosis of prostate cancer, with more cancers being detected at an earlier stage. The need for staging of prostate cancer is important for optimal management, which includes radical prostatectomy for organ confined disease, and androgen deprivation therapy for metastatic disease. Forty one percent of patients in our study had skeletal metastases as assessed on bone scans using methods for which good reliability was demonstrated. This is over twice the proportion seen in the systematic review by Abuzallouf and colleagues where 1453 of 8644 patients (16.8%) had positive bone scans. Possible explanations for the large difference may be due to inclusion of solely Black African patients in the present study. Data from other Black populations has shown higher prostate cancer incidence and mortality within men of African descent consistent with a truly greater prevalence of the disease in this group. 1 Fifty six percent of patients in our study had a prostate specific value greater than or equal to 20 ng/ml, whilst 44.3% had a prostate specific antigen level of below 20 ng/ml. A considerable difference is seen between the present findings, compared to those from the meta-analysis where 27.8% of patients had a prostate specific antigen of greater than or equal to 20 ng/ml, and 72.2% had a prostate specific antigen of less than 20 ng/ml. This reflects the case mix and inclusion criteria in reported studies, with many reporting results of evaluation for skeletal metastases at prostate specific antigen levels less than 20 ng/ml. 9
10 The mean prostate specific antigen level was 5 times higher in patients with skeletal metastases than those without skeletal metastases in the current study, a finding expected, considering the incidence of skeletal metastases increases with an increase in prostate specific antigen levels. Of the patients without metastases, most were in the low prostate specific antigen group, as indicated by a median prostate specific antigen value of 15.2 ng/ml. Within the high prostate specific antigen group the median prostate specific antigen was 86 ng/ml. An important observation with clinical implications in our sample is the wide distribution of prostate specific antigen levels amongst patients with skeletal metastases, including those below 20 ng/ml. We documented a higher prevalence of skeletal metastasis in the regional Black African population relative to the typical global pattern, especially those with a low prostate specific antigen. Indeed, the prevalence of metastasis was considerably greater than that seen in East Asian studies and among Arab populations which is consistent with existing data which indicate that these ethnic groups have a lower incidence and mortality from prostate cancer Five studies from the systematic review reported a prevalence of skeletal metastases above 10% at prostate specific antigen levels below 20ng/ml, with reported ranges from 11.7% to 15.9% Prevalence of skeletal metastasis in these studies is still noted to be somewhat lower than the current study population. A possible reason for this is the ethnic differences of patients in these studies from the current study which exclusively evaluated Black African males. Our findings are consistent with a conclusion that skeletal metastases from prostate cancer occur earlier in men of African descent, and that the biological aggressiveness of prostate cancer within this population may be higher than that seen within non Black African male populations. These findings parallel reports that the incidence of and mortality rates from prostate cancer within the East African region are high. 2 10
11 In the current study, the spine, pelvis and ribs were the commonest sites of skeletal metastasis. Probable reasons for this include the fact that the above sites are abundant in cancellous bone, which has a rich blood supply. During passage of blood through tight sinusoids in this bone structure, there is slowing of blood flow allowing deposition of tumour cells. In addition, tethering proteins like Vascular Cell Adhesion Molecule 1 (VCAM 1) are moderately expressed and interact with neoplastic cells, anchoring them to bone. 16 This pathophysiological mechanism also explains why the upper and lower limbs are affected (32% and 20% respectively), however does not explain why this is less than the previously described regions. A possible explanation is the conversion of red marrow, and subsequent reduction in blood supply to the bone marrow compared to the previously described areas, where residual red marrow exists in relative abundance CONCLUSIONS The results from the present study suggests that prostate cancer within the East African native male population demonstrates aggressive biological behaviour, similar to that seen in African American populations. We consider our findings to require that bone scans are ordered for prostate cancer patients with prostate specific antigen levels less than 20 ng/ml, and in our setting, those with levels less than 10 ng/ml should also be investigated. The need for scanning is obviously greater if patients have coexisting risk factors for skeletal metastasis such as high Gleason s scores, or extra prostatic disease extension, and there is therefore a role for further research in this field locally. Establishing the infrastructure and logistics required to run a nuclear medicine facility are challenging in low resource settings. Aspects of this are training and retention of specialist personnel, consistent procurement of radionuclide generators and radiopharmaceuticals, the 11
12 maintenance of infrastructure that meets radiation safety standards and the ability to sustain the service through realistic cost recovery and adequate volume of cases referred for investigation. We consider that the appropriate way forward is to concentrate such services within larger tertiary referral centres alongside arrangements to enable wide access through effective referral linkages that deal with practical arrangements such as travel and accommodation. In sub-saharan Africa, resourcing such developments may be best undertaken via public-private collaboration around cancer services using mechanisms such as service level agreements involving partners at regional as well as national level, as for many countries undertaking these developments would be unrealistic. Furthermore, some countries are currently developing or implementing national cancer strategies so related regional collaboration would be timely. 12
13 REFERENCES 1. Cancer facts and figures American Cancer Society. Atlanta [accessed 25/04/2012] 2. Global Cancer Facts & Figures 2nd Edition. Atlanta: American Cancer Society; [accessed 25/04/2012] ent/acspc pdf 3. Prostate Specific Antigen Best Practice Statement: 2009 Update American Urological Association [accessed 25/04/2012] 4. Guidelines on Prostate Cancer European Association of Urology 2011[accessed 25/04/2012] 5. Kamidono S, Ohshima S, Hirao Y, Suzuki K, Arai Y, Fujimoto H et al. Evidence-based Clinical Practice Guidelines for Prostate Cancer (Summary JUA 2006 Edition) Int J Urol. 2008; 15(1): Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature J Urol. 2004; 171(6 pt 1): Hirobe M, Takahashi A, Hisasue S, Kitamura H, Kunishima Y, Masumori N et al. Bone scanning - Who Needs it Among Patients with Newly Diagnosed Prostate Cancer? Jpn J ClinOncol 2007; 37(10)
14 8. Lee SH, Chung MS, Park KK, Yom CD, Lee DH, Chung BH. Is it suitable to eliminate bone scan for prostate cancer patients with PSA <20 ng/ml? World J Urol. 2012; 30: Janane A, Jawad C, Hajji F, Ould T, Ghadouane M, Ameur A et Al. Bone scan findings in a North African ethnic group and relation to PSA level and Gleason score of the biopsy. ActasUrol Esp. 2011; 35(9): Al-Ghazo MA, Ghalayini IF, Al-Azab RS, Bani-Hani I, Barham A, Haddad Y.Do All Patients with Newly Diagnosed Prostate Cancer Need Staging Radionuclide Bone Scan? A Retrospective Study. IntBraz J Urol. 2010; 36(6): Miller PD, Eardley I, Kirby RS. Prostate specific antigen and bone scan in the staging and monitoring of patients with prostate cancer Br J Urol1992; 70(3): Rudoni M, Antonini G, Favro M, Baroli A, Brambilla M, Cardani G et al: The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur J Nucl Med. 1995; 22: Ataus S, Citci A, Alici B, Onder A. U, Sonmezoglu K, Erozenciet al: The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer. IntUrolNephrol. 1999; 31(4):
15 14. Bruwer G, Heyns CF, Allen FJ. Influence of local tumour stage and grade on reliability of serum prostate specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate. Eur Urol. 1999; 35(3): Wymenga LF, Boomsma JH, Groenier K, Piers DA, Mensink H.J: Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int. 2001; 88(3): Thobe MN, Clark RJ, Bainer RO, Prasad SM, Rinker-Schaeffer CW. From Prostate to Bone: Key Players in Prostate Cancer Bone Metastasis. Cancers (Basel) 2011; 3(1):
University of Groningen
University of Groningen Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase Wymenga, LFA; Boomsma, JHB; Groenier, K; Piers, DA; Mensink,
More informationExamining the value PSA=10ng/ml as a cutoff for predicting metastatic bone disease in NaF18 PET/CT bone scans, a pilot study
ORIGINAL RESEARCH Examining the value PSA=10ng/ml as a cutoff for predicting metastatic bone disease in NaF18 PET/CT bone scans, a pilot study Aung Z. Win 1, Carina M. Aparici 2 1. Dept. Radiology, Nuclear
More informationBone Scanning Who Needs it Among Patients with Newly Diagnosed Prostate Cancer?
Bone Scanning Who Needs it Among Patients with Newly Diagnosed Prostate Cancer? Megumi Hirobe 1, Atsushi Takahashi 1, Shin-ichi Hisasue 1, Hiroshi Kitamura 1, Yasuharu Kunishima 1, Naoya Masumori 1, Akihiko
More informationWhole Body MRI. Dr. Nina Tunariu. Prostate Cancer recurrence, progression and restaging
Whole Body MRI Prostate Cancer recurrence, progression and restaging Dr. Nina Tunariu Consultant Radiology Drug Development Unit and Prostate Targeted Therapies Group 12-13 Janeiro 2018 Evolving Treatment
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationDuctal adenocarcinoma of the prostate: A clinicopathological study
20 B. SATHESAN, S. A. S. GOONEWARDENA, H. W. D. ANURUDDHIKA AND M. V. C. DE SILVA Sri Lanka Journal of Urology, 2008, 9, 20-24 Original Article Ductal adenocarcinoma of the prostate: A clinicopathological
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationBone Metastases in Muscle-Invasive Bladder Cancer
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationUsing PET/CT in Prostate Cancer
Using PET/CT in Prostate Cancer Legal Disclaimer These materials were prepared in good faith by MITA as a service to the profession and are believed to be reliable based on current scientific literature.
More informationA Competing Risk Analysis of Men Age Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer
A Competing Risk Analysis of Men Age 55-74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer Peter C. Albertsen, MD 1 James A. Hanley, PhD 2 Donald F.Gleason, MD, PhD 3
More informationLouisa Fleure. Advanced Prostate Cancer Clinical Nurse Specialist. Guys and St Thomas NHS Trust
Louisa Fleure Advanced Prostate Cancer Clinical Nurse Specialist Guys and St Thomas NHS Trust The classification of advanced prostate cancer The incidence of patients presenting with, or developing advanced
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationORIGINAL ARTICLE ABSTRACT
ORIGINAL ARTICLE 99m Tc MDP Bone Scan in Lung Cancer: Predilection Sites for Metastasis Shamim M F Begum, Zeenat Jabin, Rahima Perveen, Nasreen Sultana, Laila S Banu National Institute of Nuclear Medicine
More informationAustin Radiological Association Nuclear Medicine Procedure PROSTATE CANCER STUDY (In-111-Capromab Pendetide [ProstaScint ])
Austin Radiological Association Nuclear Medicine Procedure PROSTATE CANCER STUDY (In-111-Capromab Pendetide [ProstaScint ]) Overview Indications The Prostate Cancer Study with an indium-111 labeled murine
More informationResearch Article Bone Scan Is of Doubtful Value as a First Staging Test in the Primary Presentation of Prostate Cancer
International Scholarly Research Network ISRN Oncology Volume 2012, Article ID 585017, 6 pages doi:10.5402/2012/585017 Research Article Bone Scan Is of Doubtful Value as a First Staging Test in the Primary
More informationTHE ADVANTAGES OF bone scintigraphy for patients with
CLINICAL NUCLEAR MEDICINE Volume 27, Number 8, pp 567 571 2002, Lippincott Williams & Wilkins, Inc. Clinical Significance of Solitary Rib Hot Spots on Bone Scans in Patients with Extraskeletal Cancer Correlation
More informationPredictors of Positive Bone Metastasis in Newly Diagnosed Prostate Cancer Patients
RESEARCH ARTICLE Predictors of Positive Bone Metastasis in Newly Diagnosed Prostate Cancer Patients Tsu-Ming Chien 1,2, Yen-Man Lu 1,2, Jiun-Hung Geng 1,2, Tsung-Yi Huang 1,2, Hung- Lung Ke 1,2, Chun-Nung
More informationProstate Cancer and PSMA:
Prostate Cancer and PSMA: The Clinical Perspective from Liverpool. Dr. Christopher Mayes. Professor Sobhan Vinjamuri. Department of Nuclear Medicine Royal Liverpool University Hospital (BSUR 2016 Plymouth)
More informationGuidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationADENOCARCINOMA OF THE PROSTATE
Ref : ADENOCARCINOMA OF THE PROSTATE Div. of Urology, Dept. Surgery Medical Faculty, University of Sumatera Utara Clinical Manual of Urology, (Philip M. Hanno et al eds), McGraw-Hill Int ed, 3 rd ed, 2001
More informationCase Report New Primary Malignancy Masquerading as Metastatic Prostate Adenocarcinoma
Case Reports in Oncological Medicine Volume 2015, Article ID 358572, 5 pages http://dx.doi.org/10.1155/2015/358572 Case Report New Primary Malignancy Masquerading as Metastatic Prostate Adenocarcinoma
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationNuclear Medicine: Manuals. Nuclear Medicine. Nuclear imaging. Emission imaging: study types. Bone scintigraphy - technique
Nuclear Medicine - Unsealed radioactive preparations the tracer mixes with the patients body fluids on a molecular level (e.g. after intravenous injection) - 3 main fields: - In vitro : measuring concentrations
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationReview of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases
Original Article Review of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases Edmund Chiong, 1,2 Alvin Fung Wean Wong, 2 Yiong Huak Chan 3 and Chong Min Chin, 1,2 1 Department of Surgery,
More informationShort summary of published results of PET with fluoromethylcholine (18F) in prostate cancer
Short summary of published results of PET with fluoromethylcholine (18F) in prostate cancer JN TALBOT and all the team of Service de Médecine Nucléaire Hôpital Tenon et Université Pierre et Marie Curie,
More informationAustin Radiological Association Nuclear Medicine Procedure BONE MINERAL STUDY (Tc-99m-MDP, Tc-99m-HMDP)
Austin Radiological Association Nuclear Medicine Procedure BONE MINERAL STUDY (Tc-99m-MDP, Tc-99m-HMDP) Overview The Bone Mineral Study, with either Tc-99m-MDP or Tc-99m-HMDP, depicts the distribution
More informationThe Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer
Research Article TheScientificWorldJOURNAL (005) 5, 8 4 ISSN 57-744X; DOI 0.00/tsw.005.9 The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage
More informationLouisa Fleure. Advanced Prostate Cancer Clinical Nurse Specialist. Guys and St Thomas NHS Trust
Louisa Fleure Advanced Prostate Cancer Clinical Nurse Specialist Guys and St Thomas NHS Trust The classification of advanced prostate cancer The incidence of patients presenting with, or developing advanced
More informationVALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE. ELENA CASTRO Spanish National Cancer Research Centre
VALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 17-18 October 2017 Prostate Specific Antigen (PSA) has a role in:
More informationDenominator Criteria (Eligible Cases): Patient encounter during the performance period (CPT): 78300, 78305, 78306, 78315, 78320
Quality ID #147: Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS
More informationEssential Initial Activities and Clinical Outcomes
Essential Initial Activities and Clinical Outcomes Crystal Farrell 1,2 & Sabrina L. Noyes 2, Joe Joslin 2, Manish Varma 2,3, Andrew Moriarity 2,3, Christopher Buchach 2,3, Leena Mammen 2,3, Brian R. Lane
More informationStaging of Prostatic Carcinoma - The evolving use of SPECT-CT and Positron Emission Tomography (PET)
Staging of Prostatic Carcinoma - The evolving use of SPECT-CT and Positron Emission Tomography (PET) Poster No.: C-2477 Congress: ECR 2015 Type: Educational Exhibit Authors: B. Rawal, N. Vasdev, R. P.
More informationThe management and treatment options for secondary bone disease. Dr Jason Lester Clinical Oncologist Velindre Cancer Centre
The management and treatment options for secondary bone disease Dr Jason Lester Clinical Oncologist Velindre Cancer Centre Aims Overview of bone metastases management in castrate-refractory prostate cancer
More informationDr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationFactors Associated with Initial Treatment for Clinically Localized Prostate Cancer
Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer Preliminary Results from the National Program of Cancer Registries Patterns of Care Study (PoC1) NAACCR Annual Meeting
More informationHybrid bone scintigraphy in gastrointestinal malignancies Institutional Experience
Hybrid bone scintigraphy in gastrointestinal malignancies Institutional Experience Nazia Rashid 1, Saima Riaz 1, Humayun Bashir 1, Shafqat Mehmood 2 1 Nuclear Medicine Department ad 2 Internal Medicine
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationWhole body F-18 sodium fluoride PET/CT in the detection of bone metastases in patients with known malignancies: A pictorial review
Whole body F-18 sodium fluoride PET/CT in the detection of bone metastases in patients with known malignancies: A pictorial review Poster No.: C-1196 Congress: ECR 2014 Type: Educational Exhibit Authors:
More informationJanuary Abiraterone pre-docetaxel for patients with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone pre-docetaxel for asymptomatic/minimally symptomatic metastatic castration resistant prostate cancer Abiraterone pre-docetaxel for patients with asymptomatic
More informationAtlas of Bone Scintigraphy in the Developing Paediatric Skeleton. The Normal Skeleton, Variants and Pitfalls
Atlas of Bone Scintigraphy in the Developing Paediatric Skeleton The Normal Skeleton, Variants and Pitfalls FOREWORD Since the introduction of Technetium 99m polyphosphate in 1972 by Dr. M. Subramanian,
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationThe Importance of Prognostic Factors in Advanced Prostate Cancer
The Importance of Prognostic Factors in Advanced Prostate Cancer MarkS. Soloway, MD Three factors were identified in a multivariate analysis of prognostic factors in men with metastatic prostate cancer
More informationPI-RADS classification: prognostic value for prostate cancer grading
PI-RADS classification: prognostic value for prostate cancer grading Poster No.: C-1622 Congress: ECR 2014 Type: Scientific Exhibit Authors: I. Platzek, A. Borkowetz, T. Paulus, T. Brauer, M. Wirth, M.
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Radium-223 chloride for the treatment of bone metastases in castrate resistant prostate cancer Draft scope Draft
More informationINDICATIONS AND USAGE
1. INDICATIONS AND USAGE a) Axumin is indicated for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following
More informationProstate Overview Quiz
Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More informationNICE BULLETIN Diagnosis & treatment of prostate cancer
Diagnosis & treatment of prostate cancer NICE provided the content for this booklet which is independent of any company or product advertised Diagnosis and treatment of prostate cancer Introduction In
More informationOMPRN Pathology Matters Meeting 2017
OMPRN Pathology Matters Meeting 2017 Pathology of Aggressive Prostate Cancer Intraductal Carcinoma and Cribriform Carcinoma Dr. Michelle Downes, Staff Urologic Pathologist Sunnybrook Health Sciences Centre,
More informationWhen to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study
Lin et al. BMC Urology (2017) 17:41 DOI 10.1186/s12894-017-0229-z RESEARCH ARTICLE Open Access When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study
More informationGonzález-Sistal, A. Diagnostic Imaging Modalities of Osteoblastic Metastases. Hospital Imaging & Radiology Europe, 2 (1): (2007)
Post print version: González-Sistal, A. Diagnostic Imaging Modalities of Osteoblastic Metastases. Hospital Imaging & Radiology Europe, 2 (1): 16-17 (2007) Tittle: Diagnostic imaging modalities of osteoblastic
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationEffect of intravenous contrast medium administration on prostate diffusion-weighted imaging
Effect of intravenous contrast medium administration on prostate diffusion-weighted imaging Poster No.: C-1766 Congress: ECR 2015 Type: Authors: Keywords: DOI: Scientific Exhibit J. Bae, C. K. Kim, S.
More informationS1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES
Prostate Cancer Histopathology Reporting Proforma (Radical Prostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth Indigenous
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationNuclear Medicine in Thyroid Cancer. Phillip J. Koo, MD Division Chief of Diagnostic Imaging
Nuclear Medicine in Thyroid Cancer Phillip J. Koo, MD Division Chief of Diagnostic Imaging Financial Disclosures Bayer Janssen Learning Objectives To learn the advantages and disadvantages of SPECT/CT
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More informationNon-systemic treatment of low-volume metastatic disease.
Non-systemic treatment of low-volume metastatic disease. Gert De Meerleer, M.D., Ph.D. Gent University Hospital om behalf of POMP study group Background Patients with metastatic prostate cancer are considered
More informationPET-MRI in malignant bone tumours. Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany
PET-MRI in malignant bone tumours Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany Content From PET to PET/MRI General considerations Bone metastases Primary bone tumours
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation
More informationS1.04 Principal clinician. G1.01 Comments. G2.01 *Specimen dimensions (prostate) S2.02 *Seminal vesicles
Prostate Cancer Histopathology Reporting Proforma (Radical Prostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth Sex Male
More informationBone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When PET Scans Findings Are Equivocal: A Case Report
Bone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When Scans Findings Are Equivocal: A Case Report Yuk-Wah Tsang 1, Jyh-Gang Leu 2, Yen-Kung Chen 3, Kwan-Hwa Chi 1,4
More informationRegional difference in cancer detection rate in prostate cancer screening by a local municipality in Japan
Original Article Prostate Int 14;2(1):19- http://dx.doi.org/.12954/pi.135 P ROSTATE INTERNATIONAL Regional difference in cancer detection rate in prostate cancer screening by a local municipality in Japan
More informationLocalized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA
Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA ESMO Cape Town 14 Feb 2018 Disclosures Advisory boards/lecturer/consultant-
More informationProstate cancer smart screening, precision diagnosis, personalised treatment'
Prostate cancer smart screening, precision diagnosis, personalised treatment' Prof. Hashim Ahmed PhD, FRCS(Urol), BM, BCh (Oxon), BA(Hons) Consultant Urological Surgeon Bupa Cromwell Hospital Clinics:
More informationMetachronous anterior urethral metastasis of prostatic ductal adenocarcinoma
http://dx.doi.org/10.7180/kmj.2016.31.1.66 KMJ Case Report Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma Jeong Hyun Oh 1, Taek Sang Kim 1, Hyun Yul Rhew 1, Bong Kwon Chun
More informationCancer in Ireland : Annual Report of the National Cancer Registry
Cancer in Ireland 1994-213: Annual Report of the National Cancer Registry 215 Page 3 ABBREVIATIONS 95% CI 95% confidence interval APC Annual percentage change ASR Age-standardised rate (European standard
More informationAlthough current American Cancer Society guidelines
ORIGINAL ARTICLE Diffuse Adenosis of the Peripheral Zone in Prostate Needle Biopsy and Prostatectomy Specimens Tamara L. Lotan, MD* and Jonathan I. Epstein, MD*w z Abstract: We have observed a group of
More informationCombined SPECT/CT bone scintigraphy; a superior technique for diagnosis of benign and malignant conditions in the spine.
Combined SPECT/CT bone scintigraphy; a superior technique for diagnosis of benign and malignant conditions in the spine. Poster No.: C-1686 Congress: ECR 2011 Type: Authors: Keywords: DOI: Educational
More informationNuclear medicine in oncology. 1. Diagnosis 2. Therapy
Nuclear medicine in oncology 1. Diagnosis 2. Therapy Diagnosis - Conventional methods - Nonspecific radiopharmaceuticals cumulating in tumours - Specific radiopharmaceuticals (receptor- and immunoscintigraphy)
More informationPROSTATE CANCER: Meeting a Community Need
outcomes REPORT 2017 PROSTATE CANCER: Meeting a Community Need 1 in 6 men will be diagnosed with prostate cancer in their lifetime. 1 southnassau.org/cancer outcomes REPORT 2017 Within the primary service
More informationPET/CT imaging and RIT of prostate cancer. Kirsten Bouchelouche, MD, DMSc PET & Cyclotron Unit Rigshospitalet, Copenhagen Denmark
PET/CT imaging and RIT of prostate cancer Kirsten Bouchelouche, MD, DMSc PET & Cyclotron Unit Rigshospitalet, Copenhagen Denmark Prostate cancer Prostate cancer is the most common malignancy in men Imaging
More informationPrimary hyperparathyroidism (HPT) has an incidence of
Dual-Phase Tc-Sestamibi Imaging: Its Utility in Parathyroid Hyperplasia and Use of Immediate/ Delayed Image Ratios to Improve Diagnosis of Hyperparathyroidism Leonie Gordon, MD; William Burkhalter, MD;
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationName of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb ligand
Page 2 of 1765 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Denosumab (AMG 162) Name of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb
More informationREVIEW. Distinguishing benign from malignant adrenal masses
Cancer Imaging (2003) 3, 102 110 DOI: 10.1102/1470-7330.2003.0006 CI REVIEW Distinguishing benign from malignant adrenal masses Isaac R Francis Professor of Radiology, Department of Radiology, University
More information11/10/2015. Prostate cancer in the U.S. Multi-parametric MRI of Prostate Diagnosis and Treatment Planning. NIH estimates for 2015.
Multi-parametric MRI of Prostate Diagnosis and Treatment Planning Temel Tirkes, M.D. Associate Professor of Radiology Director, Genitourinary Radiology Indiana University School of Medicine Department
More informationProstate Cancer. Axiom. Overdetection Is A Small Issue. Reducing Morbidity and Mortality
Overdetection Is A Small Issue (in the context of decreasing prostate cancer mortality rates and with appropriate, effective, and high-quality treatment) Prostate Cancer Arises silently Dwells in a curable
More informationGa 68 -HBED- PSMA. A/ProfLouise Emmett St Vincent s Hospital Sydney
Ga 68 -HBED- PSMA A/ProfLouise Emmett St Vincent s Hospital Sydney Glu-NH-CO-NH-Lys-(Ahx)- [68Ga(HBED-CC)] Prostate specific membrane antigen 35 pub-med publications 15 clinical 3 retrospective larger
More informationProstate MRI: Who needs it?
Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center
More informationJoint Comments on Positron Emission Tomography (NaF-18) to Identify Bone Metastasis of Cancer (CAG-00065R1)
July 2, 2009 Tamara Syrek Jensen, J.D. Acting Director, Coverage and Analysis Group Centers for Medicare & Medicaid Services 7500 Security Blvd., Mail Stop C1-09-06 Baltimore, MD 21244 Re: Joint Comments
More informationCase 4: Disseminated bone metastases from differentiated follicular thyroid cancer
Case 4: Disseminated bone metastases from differentiated follicular thyroid cancer Giuliano Mariani Regional Center of Nuclear Medicine, University of Pisa Medical School, Pisa (Italy) Disseminated bone
More informationStereotactic body radiation therapy in oligometastatic patient with lymph node recurrent prostate cancer: a single centre experience.
Stereotactic body radiation therapy in oligometastatic patient with lymph node recurrent prostate cancer: a single centre experience. Elisabetta Ponti MD, Gianluca Ingrosso MD, Alessandra Carosi PhD, Luana
More informationCauses of death in men with prostate cancer: an analysis of men from the Thames Cancer Registry
Causes of death in men with prostate cancer: an analysis of 5 men from the Thames Cancer Registry Simon Chowdhury, David Robinson, Declan Cahill*, Alejo Rodriguez-Vida, Lars Holmberg and Henrik Møller
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker CEO Jefferies Healthcare Conference June 8, 2017 DISCLOSURE NOTICE This presentation may contain projections and other forward-looking statements regarding future
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More information2. The effectiveness of combined androgen blockade versus monotherapy.
Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer Blue Cross and Blue Shield Association, Aronson N, Seidenfeld J Authors' objectives
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationPET in Prostate Cancer
PET in Prostate Cancer Tom R. Miller, M.D., Ph.D. Mallinckrodt Institute of Radiology Washington University School of Medicine St. Louis, Missouri, USA Prostate Imaging Bone Scintigraphy primarily for
More informationLow risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer
Evidence-based utilization of imaging in prostate cancer Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Objectives State the modalities,
More informationHelping you make better-informed decisions 1-5
Helping you make better-informed decisions 1-5 The only test that provides an accurate assessment of prostate cancer aggressiveness A prognostic medicine product for prostate cancer. A common diagnosis
More informationPrediction of Lymph Node Involvement in Patients with Breast Tumors Measuring 3 5 cm in a Middle-Income Setting: the Role of CancerMath
DOI 10.1007/s00268-014-2752-3 BRIEF ORIGINAL SCIENTIFIC REPORT Prediction of Lymph Node Involvement in Patients with Breast Tumors Measuring 3 5 cm in a Middle-Income Setting: the Role of CancerMath E.
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More information